Sahin, Ugur http://orcid.org/0000-0003-0363-1564
Muik, Alexander http://orcid.org/0000-0003-4561-2273
Vogler, Isabel http://orcid.org/0000-0001-9757-9618
Derhovanessian, Evelyna
Kranz, Lena M. http://orcid.org/0000-0003-1943-3431
Vormehr, Mathias http://orcid.org/0000-0001-7788-3380
Quandt, Jasmin http://orcid.org/0000-0001-9589-9941
Bidmon, Nicole
Ulges, Alexander
Baum, Alina
Pascal, Kristen E. http://orcid.org/0000-0003-4826-4606
Maurus, Daniel http://orcid.org/0000-0003-2989-264X
Brachtendorf, Sebastian
Lörks, Verena http://orcid.org/0000-0003-0673-9386
Sikorski, Julian
Koch, Peter http://orcid.org/0000-0002-0638-0433
Hilker, Rolf http://orcid.org/0000-0002-8576-7731
Becker, Dirk http://orcid.org/0000-0002-4786-9331
Eller, Ann-Kathrin
Grützner, Jan
Tonigold, Manuel
Boesler, Carsten
Rosenbaum, Corinna
Heesen, Ludwig
Kühnle, Marie-Cristine http://orcid.org/0000-0003-0256-5542
Poran, Asaf http://orcid.org/0000-0001-9118-1051
Dong, Jesse Z. http://orcid.org/0000-0002-4877-852X
Luxemburger, Ulrich http://orcid.org/0000-0003-3505-3236
Kemmer-Brück, Alexandra
Langer, David
Bexon, Martin http://orcid.org/0000-0002-5361-4343
Bolte, Stefanie
Palanche, Tania
Schultz, Armin
Baumann, Sybille
Mahiny, Azita J. http://orcid.org/0000-0001-9331-5869
Boros, Gábor http://orcid.org/0000-0002-8668-9800
Reinholz, Jonas http://orcid.org/0000-0003-2384-8541
Szabó, Gábor T. http://orcid.org/0000-0001-9880-0425
Karikó, Katalin http://orcid.org/0000-0002-1864-3851
Shi, Pei-Yong http://orcid.org/0000-0001-5553-1616
Fontes-Garfias, Camila http://orcid.org/0000-0002-1912-8413
Perez, John L.
Cutler, Mark
Cooper, David
Kyratsous, Christos A. http://orcid.org/0000-0002-2596-2906
Dormitzer, Philip R. http://orcid.org/0000-0003-0671-6360
Jansen, Kathrin U.
Türeci, Özlem
Article History
Received: 9 December 2020
Accepted: 19 May 2021
First Online: 27 May 2021
Competing interests
: Ö.T. and U.S. are management board members and employees at BioNTech SE (Mainz, Germany); A.K.-B., A.M., A.J.M., A.-K.E., A.U., C.R., D.B., D.L., D.M., E.D., G.B., G.T.S., I.V., J.G., J.Q., J.R., J.S., K.K., L.H., L.M.K., M.-C.K., M.V., N.B., P.K., R.H., S. Bolte, S. Brachtendorf, T.P., U.L. and V.L. are employees at BioNTech SE; A.P. and J.Z.D. are employees at BioNTech US; M.B. is an employee at Bexon Clinical Consulting LLC; A.B., C.A.K. and K.E.P. are employees of Regeneron Pharmaceuticals Inc; A.M., K.K., Ö.T. and U.S. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccines; A.K.-B., A.M., A.J.M., A.P., C.R., D.B., D.L., E.D., G.B., I.V., J.Z.D., J.G., K.K., L.H., L.M.K., M.V., N.B., Ö.T., R.H., S. Bolte, U.L. and U.S. have securities from BioNTech SE; D.C., J.L.P., K.U.J., M.C. and P.R.D. are employees at Pfizer and may have securities from Pfizer; C.A.K. is an officer at Regeneron Pharmaceuticals, Inc; A.B., C.A.K. and K.E.P. have securities from Regeneron Pharmaceuticals, Inc; C.F.-G. and P.-Y.S. received compensation from Pfizer to perform the neutralization assay; the authors declare that there are no other relationships or activities that could appear to have influenced the submitted work.
Free to read: This content has been made available to all.